Icon Plc ( (ICLR) ) has released its Q1 earnings. Here is a breakdown of the information Icon Plc presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ICON plc, headquartered in Dublin, Ireland, is a leading clinical research organization that provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations globally.
In the first quarter of 2025, ICON plc reported net business wins of $2,022 million and a closing backlog of $24.7 billion. The company’s revenue for the quarter was $2,001.3 million, with an adjusted EBITDA of $390.7 million, representing 19.5% of revenue.
Key financial metrics for the quarter included a GAAP net income of $154.2 million, translating to $1.90 per diluted share, and an adjusted net income of $258.3 million, or $3.19 per diluted share. The company also repurchased $250 million worth of stock and reported a net debt of $2.9 billion.
Despite facing challenges such as delays in customer decision-making and trial cancellations, ICON maintained its adjusted EBITDA margin and earnings per share in line with expectations through focused resource utilization and cost control. The company updated its full-year 2025 financial guidance, excluding two large COVID vaccine trials, with anticipated revenue between $7,750 and $8,150 million.
Looking ahead, ICON plc remains committed to managing its resources effectively to deliver critical development programs for its customers, despite the ongoing volatility in the clinical development market.